Detalhe da pesquisa
1.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
N Engl J Med
; 389(2): 148-157, 2023 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272527
2.
Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
Blood
; 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38557775
3.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
N Engl J Med
; 386(7): 640-654, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34891224
4.
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7).
Blood Cancer Discov
; 5(1): 21-33, 2024 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37983485
5.
Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.
Blood Adv
; 2024 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38315832
6.
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma.
Nat Med
; 30(2): 507-518, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38233586
7.
A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors.
Clin Cancer Res
; 25(8): 2414-2423, 2019 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30366938
8.
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study.
Exp Hematol Oncol
; 6: 27, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29026685
9.
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
Clin Lung Cancer
; 18(6): 615-625.e8, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28601388